Skip to main content
Clinical Trials/CTRI/2014/12/005265
CTRI/2014/12/005265RecruitingPhase 3

Randomized placebo controlled study of the effect of Ranolazine on HbA1c level in Type 2 diabetes mellitus

IPGMER0 sites86 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 3
Status
Recruiting
Sponsor
Enrollment
86

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 18 to65 years old
  • Subjects with T2DM currently on non-insulin antidiabetic therapy (metformin) in addition to diet and exercise
  • Body mass index (BMI) >= 20 kg/m2 and <= 35 kg/m2
  • HbA1c 7 - 10%
  • Female of child-bearing potential must agree to use effective methods of contraception
  • Signed written informed consent

Exclusion Criteria

  • Not provided

Investigators

Sponsor
IPGMER

Similar Trials

Effect of Ranolazine on control of... | Clinical Trial